Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. (7th February 2023)

• Record Type: Journal Article
• Authors: Oppe, Mark; Muresan, Bogdan; Chan, Katie; Radu, Xenia; Schultz, Bob G.; Turpin, Robin S.; Nucit, Arnaud; Fenu, Elisabetta
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 23:Number 2(2023)
• Page Start: 205
• Page End: 213
• Publication Date: 2023-02-07
• Subjects: budget impact -- maintenance therapy -- subcutaneous formulation -- ulcerative colitis -- vedolizumab; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1080/14737167.2023.2160322
• Languages: English
• ISSNs: 1473-7167

Abstract

ABSTRACT: Background: Inflammatory bowel disease poses significant social and economic burdens. We assessed the budget impact of including the recently approved subcutaneous (SC) formulation of vedolizumab as maintenance therapy (MT) in patients with ulcerative colitis (UC) in France. Methods: A decision-analytic model was developed from a French payer's perspective over 5 years to assess budget impact of including vedolizumab SC as MT for UC following induction therapy with vedolizumab intravenous (IV), by subtracting outcomes of a 'world without vedolizumab SC' from a 'world with vedolizumab SC.' Comparators included approved therapies: infliximab (branded/biosimilar), adalimumab (branded/biosimilar), golimumab, ustekinumab, and vedolizumab IV. The model predicts drug, medical, and total costs, including indirect costs in a scenario analysis. A one-way sensitivity analysis explored the impact of varying individual parameters. Results: Including vedolizumab SC as MT following vedolizumab IV induction yielded total cost savings of €59, 176, 842 (biologic-naïve) and €22, 004, 135 (biologic-experienced) versus a world without vedolizumab SC. Including indirect costs yielded cost savings in biologic-naïve (€62, 600, 716) and biologic-experienced (€24, 314, 915) populations in a world with vedolizumab SC. Conclusions: Introducing vedolizumab SC as MT after IV induction is expected to have substantial cost savings to a health plan from a French payer's perspective versus a world without vedolizumab SC.